Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suresh Chari

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
The Oncologist|April 12, 2023
Management of Patients With Pancreatic Cancer Using the "Right Track" ModelAllison Rosenzweig, Jordan Berlin, Suresh Chari, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 15, 2006
Preoperative diagnosis of extrapancreatic neural invasion in pancreatic cancerMichael J Levy, Mark Topazian, Gary Keeney, et al.
AJR. American Journal of Roentgenology|October 27, 2004
Intraductal papillary mucinous neoplasms of the pancreas: CT patterns of recurrence and multiobserver performance in detecting recurrent neoplasm after surgical resectionJared A Christensen, J G Fletcher, Jeff L Fidler, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|June 24, 2015
Quality assessment of the guidelines on cystic neoplasms of the pancreasMassimo Falconi, Stefano Crippa, Suresh Chari, et al.
Annals of the Rheumatic Diseases|July 11, 2015
Response to: 'Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years' by Yamamoto et alJohn H Stone, Mollie N Carruthers, Mark D Topazian, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Rituximab for IgG4-related disease: a prospective, open-label trialMollie N Carruthers, Mark D Topazian, Arezou Khosroshahi, et al.
Science Translational Medicine|July 14, 2017
Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markersJungsun Kim, William R Bamlet, Ann L Oberg, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|July 5, 2020
Pancreatic ductal adenocarcinoma is associated with a unique endocrinopathy distinct from type 2 diabetes mellitusSajan Jiv Singh Nagpal, Harika Kandlakunta, Tracy Her, et al.
Gastrointestinal Endoscopy|April 29, 2004
Complications of temporary pancreatic stent insertion for pancreaticojejunal anastomosis during pancreaticoduodenectomyMichael J Levy, Suresh Chari, Douglas G Adler, et al.
Kidney International|December 21, 2012
Membranous glomerulonephritis is a manifestation of IgG4-related diseaseMariam P Alexander, Christopher P Larsen, Ian W Gibson, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
The Oncologist|April 12, 2023
Management of Patients With Pancreatic Cancer Using the "Right Track" ModelAllison Rosenzweig, Jordan Berlin, Suresh Chari, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 15, 2006
Preoperative diagnosis of extrapancreatic neural invasion in pancreatic cancerMichael J Levy, Mark Topazian, Gary Keeney, et al.
AJR. American Journal of Roentgenology|October 27, 2004
Intraductal papillary mucinous neoplasms of the pancreas: CT patterns of recurrence and multiobserver performance in detecting recurrent neoplasm after surgical resectionJared A Christensen, J G Fletcher, Jeff L Fidler, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|June 24, 2015
Quality assessment of the guidelines on cystic neoplasms of the pancreasMassimo Falconi, Stefano Crippa, Suresh Chari, et al.
Annals of the Rheumatic Diseases|July 11, 2015
Response to: 'Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years' by Yamamoto et alJohn H Stone, Mollie N Carruthers, Mark D Topazian, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Rituximab for IgG4-related disease: a prospective, open-label trialMollie N Carruthers, Mark D Topazian, Arezou Khosroshahi, et al.
Science Translational Medicine|July 14, 2017
Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markersJungsun Kim, William R Bamlet, Ann L Oberg, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|July 5, 2020
Pancreatic ductal adenocarcinoma is associated with a unique endocrinopathy distinct from type 2 diabetes mellitusSajan Jiv Singh Nagpal, Harika Kandlakunta, Tracy Her, et al.
Gastrointestinal Endoscopy|April 29, 2004
Complications of temporary pancreatic stent insertion for pancreaticojejunal anastomosis during pancreaticoduodenectomyMichael J Levy, Suresh Chari, Douglas G Adler, et al.
Kidney International|December 21, 2012
Membranous glomerulonephritis is a manifestation of IgG4-related diseaseMariam P Alexander, Christopher P Larsen, Ian W Gibson, et al.
Pageof 6